Waldenström Macroglobulinemia

Waldenström巨球蛋白血症

10.6323/JoCRP.2014.30.1.6

葉淑婷(Shu-Ting Yeh)；卓士峰(Shih-Feng Cho)；黃炯棠(Chiung-Tang Huang)

Waldenström巨球蛋白血症 ； Waldenström macroglobulinemia

台灣癌症醫學雜誌

30卷1期（2014 / 03 / 01）

48 - 52

英文

Waldenström巨球蛋白血症是一種B淋巴細胞增生而且合併單細胞免疫球IgM蛋白的疾病。通常Waldenström巨球蛋白血症的發生率大約每年每一百萬人口發生5位的案例，平均佔血液惡性疾病大約1～2%。平均診斷時的年紀大約63至68歲左右而且大多為男性。在此我們報告此罕見疾病一例。病人為60歲男性，診斷是Waldenström巨球蛋白血症，而且以腸胃道出血為表現。在使用化療處方dexamethasone，rituximab，and cyclophosphamide （DRC regimen）後，症狀與免疫球蛋白有緩解與下降的趨勢。

Waldenström macroglobulinemia is a B-cell lymphoproliferative disorder with monoclonal immunoglobulin M protein (IgM) in the serum. The overall incidence of Waldenström macroglobulinemia is approximately 5 cases per 1 million persons per year, and accounts for approximately 1 to 2% of cases of hematologic cancer. The median age at diagnosis is between 63 and 68 years, and most patients are males. Herein, we report a rare case of a 60-year-old male diagnosed to have Waldenström macroglobulinemia. After receiving a combination of dexamethasone, rituximab, and cyclophosphamide (DRC regimen), the symptoms and immunoglobulin M level gradually improved.